Pfizer Terminates Two Phase III Programs

Pfizer is terminating Phase III development programs for the investigational compounds esreboxetine for fibromyalgia and PD 332,334 for generalized anxiety disorder (GAD), following a review of the development and commercial portfolios in the Primary Care

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer is terminating Phase III development programs for the investigational compounds esreboxetine for fibromyalgia and PD 332,334 for generalized anxiety disorder (GAD), following a review of the development and commercial portfolios in the Primary Care Business Unit. According to the company, the decision will enable that unit to “allocate additional resources to higher-potential development programs.” After reviewing the Phase III results for PD 332,334 in GAD and the existing data for es...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters